Status: Recruiting
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Participants needed: 164
Trial details
Phase: Phase 2Age: 60+Biological sex: AllType: InterventionalSponsor: IGC Pharma, LLCUpdated: May 20, 2026Locations: 31
Eligibility criteria
Participant and/or Caregiver must provide a signed and dated ICF prior to any st... [+11]
Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD... [+7]